Media stories about Paratek Pharmaceuticals (NASDAQ:PRTK) have trended somewhat positive this week, according to Accern. The research group rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Paratek Pharmaceuticals earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 46.1617032556591 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Here are some of the media stories that may have impacted Accern’s rankings:

Several brokerages have weighed in on PRTK. Zacks Investment Research lowered Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday. Cantor Fitzgerald set a $50.00 target price on Paratek Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, June 11th. Finally, BidaskClub lowered Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 24th. Three research analysts have rated the stock with a sell rating and seven have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $40.00.

Paratek Pharmaceuticals traded up $0.10, hitting $10.30, during trading hours on Wednesday, according to Marketbeat Ratings. The company had a trading volume of 532,563 shares, compared to its average volume of 571,904. Paratek Pharmaceuticals has a fifty-two week low of $9.85 and a fifty-two week high of $29.00. The company has a debt-to-equity ratio of 0.47, a current ratio of 8.06 and a quick ratio of 8.06. The firm has a market capitalization of $327.02 million, a PE ratio of -3.12 and a beta of 0.58.

Paratek Pharmaceuticals (NASDAQ:PRTK) last issued its earnings results on Wednesday, May 9th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.94) by $0.03. Paratek Pharmaceuticals had a negative return on equity of 87.29% and a negative net margin of 707.08%. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.02 million. equities research analysts expect that Paratek Pharmaceuticals will post -3.68 earnings per share for the current fiscal year.

In other news, COO Evan Loh sold 12,000 shares of the stock in a transaction on Monday, July 2nd. The stock was sold at an average price of $9.97, for a total value of $119,640.00. Following the completion of the transaction, the chief operating officer now owns 202,786 shares of the company’s stock, valued at $2,021,776.42. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Chairman Michael Bigham sold 22,500 shares of the stock in a transaction on Monday, July 2nd. The stock was sold at an average price of $9.97, for a total value of $224,325.00. Following the completion of the transaction, the chairman now directly owns 177,230 shares of the company’s stock, valued at approximately $1,766,983.10. The disclosure for this sale can be found here. Insiders sold 41,823 shares of company stock worth $416,975 over the last ninety days. 6.20% of the stock is owned by corporate insiders.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.

Insider Buying and Selling by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.